Now hiring for a Director of Translational Sciences! Come join A-Alpha Bio on our quest to improve human health! This person will play a key role in establishing our clinical translational drug development capabilities. Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/gJvuFWwY
A-Alpha Bio
Biotechnology Research
Seattle, Washington 8,063 followers
The protein-protein interaction company
Über uns
A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/
- Website
-
https://www.aalphabio.com/
External link for A-Alpha Bio
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Seattle, Washington
- Typ
- In Privatbesitz
- Gegründet
- 2017
- Spezialitäten
- Drug discovery, Protein Engineering, Synthetic Biology, Immunocytokines, Molecular Glues, Oncology, and Protein-protein interactions
Standorte
-
Primäre
2101 4th Ave
Fifth Floor
Seattle, Washington 98121, US
Employees at A-Alpha Bio
Aktualisierungen
-
Now hiring for a Scientist I! Come join A-Alpha Bio on our quest to improve human health! This person will join our Immunobiology team in the discovery of novel drug candidates for our therapeutic pipeline. Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/gzNaMs2G
-
Now hiring for a Research Associate II! Come join A-Alpha Bio on our quest to improve human health! This person will join our Protein Science team to expand our mammalian protein production capabilities. Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/gm73VubK
Karriere
aalphabio.com
-
Now hiring for a Director of Communications! Come join A-Alpha Bio on our quest to improve human health! This person will lead all corporate communications functions - fostering external understanding of our platforms, therapeutic programs, corporate strategy, and industry partnerships. If you know of someone that may be a great fit, please reach out! https://lnkd.in/gAQRmDg6
Karriere
aalphabio.com
-
Now hiring for a Scientist I on our Platform R&D team! Come join A-Alpha Bio on our quest to improve human health! This person will design, execute, and analyze experiments that leverage our AlphaSeq and AlphaBind platforms for drug discovery, with a focus on biologic therapeutics. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g4duQ2iU
-
We are excited to share that A-Alpha Bio has been awarded an additional $14.5M from the United States Department of Defense to enable machine learning models that rapidly predict treatments against possible biological threats. Funding from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND will expand our partnership with Lawrence Livermore National Laboratory (LLNL) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) program. This announcement follows two years of successful collaboration between A-Alpha and LLNL – beginning with coronaviruses and expanding to multiple undisclosed pathogen families of concern – in which A-Alpha’s AlphaSeq data has been used to train ML models that predict antibody-antigen binding. We look forward to continuing and expanding the partnership! Read more in today's press release: https://lnkd.in/eVKne9eE And thanks to Genetic Engineering & Biotechnology News's Jonathan D. Grinstein, PhD for a great piece: https://lnkd.in/eXB-mufW
-
-
Now hiring for a Process Engineer I! Come join A-Alpha Bio on our quest to improve human health! This person will serve as a bridge between our Technical Operations and R&D organizations to improve efficiency and quality, troubleshoot existing processes, and facilitate the transition of new processes. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g38XNqQX
Karriere
aalphabio.com
-
Now hiring for a Scientist I, Antibody Discovery! Come join A-Alpha Bio on our quest to improve human health! This person will join our Biologics Discovery team to execute and optimize antibody discovery and assay development initiatives. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g49BJ2r7
Karriere
aalphabio.com
-
A-Alpha Bio reposted this
I'm looking forward to attending and presenting at Life Science Innovation Northwest this Thursday! This is one of my favorite annual meetings - a great opportunity to catch up with the local PNW biotech community, which has become more and more vibrant over the eight years I've been attending. I'll be giving an update on what we've been up to at A-Alpha Bio and I'm excited to hear about the new innovations, recent deals, and emerging companies in our region. I hope to see you there!
-
-
The A-Alpha team is excited to participate in the Festival of Biologics Annual Meeting in San Diego next week! During the meeting, we will share our latest work on applying AlphaSeq and AlphaBind for immunocytokine engineering. In his talk, A-Alpha Co-Founder and CEO David Younger will delve into the applications of our platforms to engineer immunocytokine therapeutics using high-throughput experiments and machine learning. A-Alpha Principal Scientist Emily Engelhart will further present a poster on how our platforms enable the discovery and optimization of highly specific cis-targeting immunocytokines. If you’re attending, catch David’s talk and visit Emily’s poster to learn more. #biotech #immunocytokines #FestivalofBiologics